Ovid Therapeutics
OVID
81 hedge funds and large institutions have $47.1M invested in Ovid Therapeutics in 2025 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 17 increasing their positions, 24 reducing their positions, and 14 closing their positions.
297% more capital invested
Capital invested by funds: $11.9M → $47.1M (+$35.2M)
79% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 14
14% more funds holding
Funds holding: 71 → 81 (+10)
0.35% more ownership
Funds ownership: 50.58% → 50.92% (+0.35%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
29% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 24
34% less call options, than puts
Call options by funds: $299K | Put options by funds: $456K
Top Buyers
| 1 |
AAA
Affinity Asset Advisors
New York
|
+$1.72M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$950K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$765K |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$542K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$536K |
Top Sellers
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$1.27M |
| 2 |
SCM
Sio Capital Management
New York
|
-$697K |
| 3 |
BlackRock
New York
|
-$657K |
| 4 |
TA
TLS Advisors
Miami,
Florida
|
-$574K |
| 5 |
MAP
Madison Avenue Partners
New York
|
-$433K |
OVID Hedge Fund Activity: Q3 2025 in Review
81 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q3 2025, worth a combined $47.1M — up 297% from $11.9M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new OVID positions and 14 closed out — a net gain of 11 holders — while 17 added to existing stakes and 24 trimmed.
The largest buyer was Affinity Asset Advisors, adding an estimated $1.72M. The largest seller was BVF Inc, exiting entirely with an estimated $1.27M sold.
- 81 institutional investors held Ovid Therapeutics (OVID) as of Q3 2025, up from 71 in Q2 2025.
- Funds reported $47.1M of Ovid Therapeutics stock for Q3 2025, up 297% quarter-over-quarter.
- 25 funds opened new Ovid Therapeutics positions in Q3 2025 and 14 closed out, a net change of +11 holders.
- The largest Ovid Therapeutics buyer in Q3 2025 was Affinity Asset Advisors, an estimated $1.72M added.
- The largest Ovid Therapeutics seller in Q3 2025 was BVF Inc, an estimated $1.27M sold.
Based on aggregated 13F filings for Q3 2025.